Clinton Group Inc. purchased a new stake in IDEXX Laboratories, Inc. (NASDAQ:IDXX) in the second quarter, according to the company in its most recent disclosure with the SEC. The firm purchased 11,108 shares of the company’s stock, valued at approximately $1,793,000.

Other large investors have also made changes to their positions in the company. UBS Asset Management Americas Inc. grew its position in IDEXX Laboratories by 21.8% in the first quarter. UBS Asset Management Americas Inc. now owns 233,209 shares of the company’s stock worth $36,056,000 after acquiring an additional 41,801 shares in the last quarter. Sei Investments Co. increased its stake in IDEXX Laboratories by 76.6% during the first quarter. Sei Investments Co. now owns 20,277 shares of the company’s stock worth $3,135,000 after acquiring an additional 8,792 shares during the last quarter. Raymond James Financial Services Advisors Inc. raised its position in IDEXX Laboratories by 46.1% during the first quarter. Raymond James Financial Services Advisors Inc. now owns 6,024 shares of the company’s stock valued at $931,000 after purchasing an additional 1,901 shares during the period. Nordea Investment Management AB raised its position in IDEXX Laboratories by 136.6% during the first quarter. Nordea Investment Management AB now owns 4,477 shares of the company’s stock valued at $692,000 after purchasing an additional 2,585 shares during the period. Finally, Victory Capital Management Inc. raised its position in IDEXX Laboratories by 11.8% during the first quarter. Victory Capital Management Inc. now owns 8,534 shares of the company’s stock valued at $1,319,000 after purchasing an additional 901 shares during the period. 87.64% of the stock is owned by hedge funds and other institutional investors.

Shares of IDEXX Laboratories, Inc. (IDXX) traded down 0.57% during trading on Tuesday, reaching $156.28. 43,042 shares of the company traded hands. The firm has a 50 day moving average of $155.48 and a 200 day moving average of $159.66. The stock has a market capitalization of $13.64 billion, a PE ratio of 53.76 and a beta of 0.48. IDEXX Laboratories, Inc. has a 52 week low of $102.45 and a 52 week high of $173.01.

IDEXX Laboratories (NASDAQ:IDXX) last announced its earnings results on Tuesday, August 1st. The company reported $0.95 EPS for the quarter, beating analysts’ consensus estimates of $0.85 by $0.10. IDEXX Laboratories had a negative return on equity of 473.46% and a net margin of 14.13%. The company had revenue of $508.90 million during the quarter, compared to analysts’ expectations of $502.44 million. During the same period last year, the business posted $0.74 EPS. IDEXX Laboratories’s revenue for the quarter was up 9.1% on a year-over-year basis. On average, equities analysts predict that IDEXX Laboratories, Inc. will post $3.18 EPS for the current year.

Several equities research analysts have recently issued reports on the company. Zacks Investment Research lowered IDEXX Laboratories from a “buy” rating to a “hold” rating in a research note on Monday, June 12th. Canaccord Genuity reiterated a “buy” rating and issued a $180.00 target price on shares of IDEXX Laboratories in a report on Tuesday, June 13th. BidaskClub downgraded IDEXX Laboratories from a “strong-buy” rating to a “buy” rating in a research report on Tuesday, June 13th. Stifel Nicolaus reissued a “buy” rating and set a $185.00 target price on shares of IDEXX Laboratories in a research report on Friday, July 14th. Finally, CL King raised IDEXX Laboratories from a “neutral” rating to a “buy” rating and set a $200.00 target price on the stock in a research report on Friday, July 28th. Two investment analysts have rated the stock with a sell rating, one has issued a hold rating and five have assigned a buy rating to the company. IDEXX Laboratories has a consensus rating of “Hold” and a consensus price target of $174.00.

In related news, Chairman Jonathan W. Ayers sold 13,000 shares of IDEXX Laboratories stock in a transaction on Monday, August 28th. The shares were sold at an average price of $150.79, for a total transaction of $1,960,270.00. Following the sale, the chairman now directly owns 1,044,034 shares in the company, valued at approximately $157,429,886.86. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink. Also, CEO Jonathan W. Ayers sold 18,000 shares of IDEXX Laboratories stock in a transaction on Monday, August 14th. The stock was sold at an average price of $154.91, for a total transaction of $2,788,380.00. Following the sale, the chief executive officer now owns 1,043,034 shares in the company, valued at $161,576,396.94. The disclosure for this sale can be found here. Over the last three months, insiders have sold 151,734 shares of company stock valued at $23,436,626. Corporate insiders own 2.77% of the company’s stock.

TRADEMARK VIOLATION NOTICE: “11,108 Shares in IDEXX Laboratories, Inc. (IDXX) Purchased by Clinton Group Inc.” was originally reported by Watch List News and is owned by of Watch List News. If you are viewing this news story on another site, it was copied illegally and republished in violation of international trademark & copyright laws. The legal version of this news story can be read at https://www.watchlistnews.com/11108-shares-in-idexx-laboratories-inc-idxx-purchased-by-clinton-group-inc/1605407.html.

IDEXX Laboratories Company Profile

IDEXX Laboratories, Inc develops, manufactures and distributes products and provides services for the companion animal veterinary, livestock and poultry, dairy and water testing markets. The Company also sells a line of portable electrolytes and blood gas analyzers for the human point-of-care medical diagnostics market.

Want to see what other hedge funds are holding IDXX? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for IDEXX Laboratories, Inc. (NASDAQ:IDXX).

Institutional Ownership by Quarter for IDEXX Laboratories (NASDAQ:IDXX)

Receive News & Ratings for IDEXX Laboratories Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for IDEXX Laboratories Inc. and related companies with Analyst Ratings Network's FREE daily email newsletter.